IN8bio financials
$1.30+4.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.9M | -$5.3M | -$5.0M | -$4.0M | -$5.2M | -$5.7M | -$6.2M | -$7.1M | -$8.7M | -$8.6M | -$7.6M | -$7.2M |
| Net income | -$4.8M | -$5.1M | -$4.9M | -$3.9M | -$5.1M | -$5.5M | -$6.2M | -$7.1M | -$8.6M | -$8.6M | -$7.6M | -$7.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.25 | $-0.26 | $-0.79 | $-0.85 | $-1.24 | $-2.16 | $-1.10 | $-4.49 | $-5.51 | $-6.00 | $-6.57 | $-6.90 |
| EBITDA | -$4.7M | -$5.0M | -$4.8M | -$3.7M | -$4.9M | -$5.4M | -$6.0M | -$6.9M | -$8.5M | -$8.4M | -$6.5M | -$7.3M |
| Operating cash flow | -$3.7M | -$4.9M | -$2.1M | -$3.5M | -$3.9M | -$3.1M | -$4.0M | -$6.1M | -$6.1M | -$7.9M | -$4.8M | -$5.7M |
| Free cash flow | -$4.0M | -$5.0M | -$2.1M | -$3.5M | -$3.9M | -$3.1M | -$4.1M | -$6.1M | -$6.2M | -$8.0M | -$5.2M | -$5.8M |
| Diluted shares | 19.5M | 19.5M | 6.3M | 4.5M | 4.1M | 2.6M | 5.6M | 1.6M | 1.6M | 1.4M | 1.2M | 1.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.0M | $21.9M | $27.1M | $10.7M | $13.2M | $11.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $126.0K | $189.0K | $295.0K | $407.0K | $530.0K | $765.0K |
| Total assets | $21.7M | $26.3M | $32.3M | $16.8M | $19.4M | $19.9M |
| Total liabilities | $3.4M | $3.5M | $4.7M | $3.6M | $4.1M | $6.0M |
| Shareholders' equity | $18.4M | $22.8M | $27.6M | $13.2M | $15.2M | $13.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology